Clinical Trial Enrollment Barriers: Awareness Isn’t the Same as Access

While clinical trials represent the cutting edge of modern cancer therapy, significant disparities persist in determining who actually enrolls in them. In this episode of Oncology Unfiltered, Dr. Matthew Hadfield and Melissa Cutrona discuss the practical, structural, and clinical hurdles that prevent eligible patients from accessing potentially lifesaving investigational therapies, and how the oncology community can translate trial availability into meaningful access. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-clinical-trial-enrollment-barriers What You’ll Learn in This Episode: 🔹 Shifting Mindsets to Frontline Therapy: Understanding how clinical trials have evolved from last-resort options to representing preferred frontline strategies and the most promising avenues in modern cancer care. 🔹 Dismantling Patient Misconceptions: Debunking common anxieties surrounding placebos and "test subject" perceptions by clarifying open-label study designs and standard-of-care backbones. 🔹 Balancing Safety with Real-World Eligibility: Analyzing the impact of overly rigid eligibility criteria and advocating for drug-specific, rationalized inclusion rules that reflect true patient populations. 🔹 Navigating "Life Eligibility" and Logistics: Addressing travel burdens, intensive monitoring schedules, and the need for empathetic, iterative patient counseling to overcome practical access barriers. 🔹 Building Community and Academic Partnerships: Strengthening reciprocal referral channels and relationships between local practices and academic cancer centers to drive trial identification and enrollment. Chapter Timestamps: About the Speakers: Matthew Hadfield, DO, is the Editor in Chief of Oncology Data Advisor.